Clinical presentation, treatment, and outcome of alveolar
soft part sarcoma in children, adolescents,
and young adults
Mark L. Kayton
a,
*, Paul Meyers
b
, Leonard H. Wexler
b
,
William L. Gerald
c
, Michael P. LaQuaglia
a
a
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
b
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
c
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Abstract
Purpose: Alveolar soft part sarcoma is a rare soft tissue neoplasm that can affect children and adolescents.
There are few reported series of these patients in the literature. To define the clinical presentation,
treatment, and outcome of young people with this rare sarcoma, we reviewed our clinical experience.
Methods: After institutional review board approval, we examined the records of all patients younger than
25 years old who received treatment at our institution for alveolar soft part sarcoma in the past 30 years.
Demographics, tumor sizes, sites and extent of disease, treatments used, progression-free survival, and
overall follow-up were evaluated.
Results: Each of the 20 patients presented with a mass. Primary disease sites were thigh (n = 8), trunk
(n = 6), retroperitoneum (n = 2), and scalp, neck, forearm, and calf (n = 1 each). Metastatic sites included
lymph nodes, lung, and brain. Four patients presented to us with incomplete excision of the primary, and
1 had undergone embolization of what was thought to be a vascular malformation. Although wide
local excision provided the best chance for a patient to remain free of disease, 14 (70%) of 20 patients
exhibited metastases either at presentation or later. Thirty-one metastasectomies were performed.
Chemotherapy was used in 11 patients; radiation was used in 8. Median overall follow-up was 36 months;
median progression-free follow-up was 12.5 months. Younger patients tended to have Intergroup
Rhabdomyosarcoma Study group I disease. Tumors smaller than 5 cm were associated with longer
progression-free survival.
Conclusions: Achievement of complete microscopic resection is critical in localized alveolar soft part
sarcoma, but incomplete excision and misdiagnosis are often encountered. Despite the occurrence of
metastases in 70% of patients, 5-year overall survival was 83%. We found an association between smaller
tumor size and longer time to progression. We were not able to demonstrate any benefit from
chemotherapy or radiation. Metastasectomies have been performed in multiple long-term survivors.
D 2006 Elsevier Inc. All rights reserved.
0022-3468/$ ­ see front matter
D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jpedsurg.2005.10.023
Presented at the 36th Annual Meeting of the American Pediatric Surgical Association, Phoenix, AZ, May 29-June 1, 2005.
* Corresponding author. Division of Pediatric Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. Tel.: +1 212 639 7966;
fax: +1 212 717 3373.
E-mail address: kaytonm@mskcc.org (M.L. Kayton).
Index words:
Alveolar soft part
sarcoma;
Soft tissue neoplasms;
Sarcoma;
Childhood;
Adolescence;
Pediatrics;
Survival;
Progression;
IRS Group
Journal of Pediatric Surgery (2006) 41, 187 ­ 193
www.elsevier.com/locate/jpedsurg